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Gastric cancer (GC) remains one of the most common types of malignant cancer, and the molecular mechanism
underlying its metastasis is still largely unclear. MicroRNAs have emerged as important regulators of metastasis because
of their ability to act on multiple signaling pathways. In our study, we found that miR-144 is significantly downregulated
in both highly metastatic GC cell lines and tissues. Results from both gain-of-function and loss-of-function experiments
demonstrate that increased miR-144 expression significantly reduced GC cell migration, whereas decreased miR-144
expression dramatically enhanced GC cell migration. The met proto-oncogene (MET), which is often amplified in human
cancers and functions as an important regulator of cell growth and tumor invasion, was identified as a direct target of
miR-144. Moreover, silencing of MET using small interfering RNA (siRNA) recapitulated the anti-metastatic function of
miR-144, whereas restoring MET expression attenuated the function of miR-144 in GC cells. Furthermore, we found that
miR-144, by targeting MET, suppresses phosphorylation of Akt. Finally, we observed an inverse correlation between the
expression of miR-144 and MET mRNA in GC metastatic tissues. In summary, miR-144 suppresses GC progression by
directly downregulating MET expression, which subsequently prevents activation of the pro-oncogenic Akt pathway.
Reintroduction of miR-144 expression in GC cells presents an attractive therapeutic approach to block the metastasis of
gastric cancer.
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Globally, gastric cancer (GC) is one of the most preva-
lent types of malignant disease. In 2008, approximately
989,600 new cases of GC were diagnosed. Furthermore,
GC was implicated as a cause of 738,000 deaths, making
GC the fourth most common malignancy and the lead-
ing cause of cancer death worldwide [1]. As the tumor
progresses, it develops the ability to invade surrounding
tissues and metastasize. The hepatocyte growth factor
receptor, MET, is known to promote the motility and in-
vasive capability of tumor cells [2]. MET is a member of
the receptor tyrosine kinase family and has been shown
to be upregulated in many tumors [3-5]. It is suggested
that MET expression level is increased by either gene
amplification or hypoxia via HIF1α. In patients with
metastatic GC, MET amplification and strong protein
expression are not infrequent. These events appear to be* Correspondence: guxixi@sina.com
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come [6]. Approximately 10% of white patients harbor a
gain of five or more copies of MET. Additionally, this
gain in MET copy number is significantly associated with
unfavorable prognosis [7]. Furthermore, the miR-34a/c
microRNAs have been shown to negatively modulate
MET expression in cell lines derived from prostate can-
cer, hepatocellular carcinoma and GC [8-10].
MicroRNAs (miRNAs) are non-coding RNA mole-
cules, approximately 21–23 nucleotides in length, which
regulate gene expression at the transcriptional or post-
transcriptional level [11-13]. miRNA expression profiling
analyses have revealed a global downregulation of ma-
ture miRNA levels in human tumors relative to normal
tissues [14]. Furthermore, miRNAs may function in ei-
ther a tumor suppressor or oncogenic role, depending
on the function of their target. For example, miR-133b
was significantly down-regulated in GC tissues and
exerted its tumor suppressor role in GC cells [15]. Ex-
pression of miR-337-3p was significantly downregulated
in lymph node metastatic tissues of GC patients, ands is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cancer cell invasion capacity [16]. miR-25 promotes GC
progression by directly downregulating TOB1 expres-
sion; therefore, increased expression of miR-25 presents
a potential noninvasive biomarker for the prognosis of
GC patients [17]. Additionally, miR-7 is significantly
downregulated in both highly metastatic GC cell lines
and metastatic tissues. Overexpression of miR-7 mark-
edly inhibits GC metastasis by targeting the expression
of the insulin-like growth factor-1 receptor (IGF1R)
oncogene [18]. In GC cell lines, reintroduction of miR-
144 expression results in repression of ZFX, which
moderately increases cancer cell susceptibility to 5-
fluorouracil chemotherapy. In 93 cases of primary GC,
diminished miR-144 expression was associated with poor
prognosis [19]. These examples have highlighted the key
role of miRNAs in GC malignance and cancer progression.
In this study, we characterized the targets and defined
the mechanism of action of miR-144 in GC. By inducing
ectopic expression of miR-144, we discovered MET is a
novel target of miR-144 regulation. This finding was
confirmed on both mRNA and protein levels, and re-
porter gene luciferase assays verified direct binding of
miR-144 to the regulatory binding site in the 3′UTR of
MET. Furthermore, we found that MET expression in-
versely correlates to miR-144 levels in a small but well-
documented GC cohort. We hypothesize that miR-144
inhibits GC metastasis, and that some of this inhibition
is mediated by targeting MET expression.
Materials and methods
Human tissue specimens and cell lines
GC samples were collected from patients who under-
went surgery at Fudan University Shanghai Cancer Cen-
ter between 2012 and 2013. The protocol was approved
by the Clinical Research Ethics Committee of Fudan
University, and the research was carried out according
to the provisions of the Helsinki Declaration of 1975. All
samples were obtained with the informed consent of the
patients. The human GC cell line AGS (ATCC® CRL-
1739™), SNU-1 (ATCC® CRL-5971™), SNU-5 (ATCC®
CRL-5973™), SNU-16 (ATCC® CRL- 5974™), NCI-N87
(ATCC® CRL-5822™), and KATO III (ATCC® HTB-103™)
were maintained in DMEM containing 10% fetal bovine
serum. All cell lines were maintained in media contain-
ing penicillin (100 IU/ml) and streptomycin (100 mg/ml)
at 37°C with 5% CO2. The miRNA mimics and inhibi-
tors were purchased from Ambion (Austin, TX, USA).
RNA extraction and real-time PCR
Total RNA was extracted from cells using TRIzol (Invi-
trogen, Carlsbad, CA). For miRNA analysis, poly(A) tails
were added to total RNA using poly(A) polymerase
(Ambion, Carlsbad, CA) prior to reverse transcription.The MiRcute miRNA qPCR detection kit (TIANGEN,
Beijing, China) was used to quantitate the expression
levels of miR-144 according to the provided protocol.
The following PCR conditions were used: 95°C for 30 s,
followed by 40 cycles of 95°C for 5 s and 60°C for 31 s.
The amount of target (MET/miR-144), normalised to
the endogenous housekeeping gene GAPDH/U6snRNA
and relative to a reference sample, is given by the follow-
ing equation: amount of target =2-△△CT.
Microarray hybridization
Briefly, RNA samples were used to synthesize double-
stranded complementary DNA (cDNA), and double-stranded
cDNA was labeled and hybridized to the Microarray
(Arraystar, Rockville, MD). After hybridization and wash-
ing, processed slides were scanned with the Axon GenePix
4000B microarray scanner (Molecular Devices, Sunnyvale,
CA). P value was calculated using the paired t-test. The
threshold set for up- and down-regulated genes was a fold
change > 2.0 and a p value < 0.05. Hierarchical clustering
was performed based on differentially expressed genes
and miRNAs using Cluster Treeview software from
Stanford University (Palo Alto, CA).
MiRNA-gene network
We constructed the network adjacency between two
genes, i and j, defined as a power of the Pearson correl-
ation between the corresponding gene-expression pro-
files, xi and xj. The adjacency matrix, M (i,j), was
visualized as a graph, and the topological properties of
this graph were examined. To make a visual representa-
tion, only the strongest correlations (>0.98) were drawn
in these renderings. In miRNA-gene networks, each
gene corresponds to a node. Two genes are connected
by an edge, indicating a strong correlation. Within the
network analysis, a degree is the simplest, most import-
ant measure of the centrality of a gene within a network
and determines the relative importance. A degree is de-
fined as the number of directly linked neighbors.
Prediction of miR-144 binding site
Putative miR-144 binding sites in MET mRNA 3′ un-
translated region were predicted by the Target Scan pro-
gram (http://www.targetscan.org). Position 1430–1436 of
MET 3′ UTR has a conserved binding site for miR-144
targeting.
Plasmid transfection
The ORF sequences of MET were amplified from gen-
omic DNA isolated from the SNU-5 cell line and were
then subcloned into the plenti vector. The plasmid was
transfected into SNU-5 cells using Lipofectamine 2000
(Invitrogen). After 24 h, the cells were used for a rescue
experiment.
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MiR-144 mimics, miR-144 inhibitor (anti–miR-144), and
MET siRNA (siRNA-MET) were synthesized by Gene-
pharma, Shanghai, China. Oligonucleotide transfection
was performed with Lipofectamine 2000 reagents (Invi-
trogen, Carlsbad, CA, USA). The final concentration of
miR-144 mimics, anti–miR-144 or siRNA-MET in the
transfection system was 100 nM. Transfection efficiency
for the single and co-transfected studies was determined
by fluorescence microscope.Immunoblotting
Equivalent amounts of cell lysates were resolved by 7%
SDS/PAGE and were transferred onto polyvinylidene
fluoride membranes. The membrane was incubated with
a rabbit polyclonal anti-MET antibody (1:500, abcam,
ab47431), a goat polyclonal anti-ADAM12 antibody (0.3
μg/ml, abcam, ab28747), and a rabbit polyclonal anti-
Versican antibody (1 μg/ml, abcam, ab19345). IRdye-
labeled secondary antibodies were used for quantitation
of the immunoblotting signal, and the signals were ana-
lyzed using an Odyssey scanner (LI-COR Biosciences,
Lincoln, NE, USA).RNA-ChIP assay
RNA-protein interactions are fixed with formaldehyde,
and chromatin shearing is combined with DNase treat-
ment to yield RNA/protein complexes that can be
immunoprecipitated with antibodies to MET proteins.
Cross-links are subsequently reversed; RNA is recovered
and again treated with DNase to ensure the absence of
DNA. RNA precipitated from the immune complex then
be analyzed by real-time PCR. In this RNA-ChIP assay,
the following formula be used: % of input (recovery) =
AE(Ct input-Ct sample) * Fd * 100%. Here, AE is the
amplification efficiency (10(−1/slope)) and Fd is a dilu-
tion factor of the input RNA to balance the difference in
the amounts of RNA-ChIP sample and input RNA used
for real-time PCR.Luciferase assay
The full MET 3′UTR was amplified by PCR using SNU-
5 cDNA as template and cloned into pGL3 control vec-
tor. We used Quick Change mutagenesis to mutate the
miR-144 putative binding site (Stratagene, Santa Clara,
CA, USA). SNU-5 cells and AGS cells were transfected
with miR-144 mimics/inhibitors and pGL3 luciferase re-
porter constructs harboring the MET 3′UTR. After 24
h, the activities of firefly luciferase and renilla luciferase
in the cell lysates were measured with the Dual-
Luciferase Assay System (Promega, Madison, WI, USA).Migration assays
For the transwell migration assays, 1 × 105 cells were
plated in the top chamber containing a non-coated
membrane. The cells were plated in the serum-free
medium, and medium supplemented with 10% (v/v)
serum was used as a chemoattractant in the lower cham-
ber. The cells were incubated at 37°C in a tissue culture
incubator with 5% (v/v) CO2. After 16 h, the non-
migrated cells were removed from the upper sides of the
transwell membrane filter inserts. The migrated cells on
the lower sides of the inserts were stained with coomas-
sie brilliant blue, and the cells were counted.Cell proliferation assay
The transfected cells were seeded in 96-well plates at a
density of 1 × 104 cells/well. A cell proliferation assay
was performed using the Cell Counting Kit-8 (Dojindo,
Kumamoto, Japan) according to the manufacturer’s in-
structions. Before the addition of CCK-8, the cells were
washed with warm culture media by spinning the plate
at 500 rpm for 3 m and then discarding the supernatant.Primers
The following primers were used for real-time PCR:
miR-144: 5-TACAG TATAG ATGAT GTACT-3;
U6snRNA: 5-CGCAA GGAUG ACACG CAAAU
UCGUG AAGCG UUCCA UAUUU UU-3; SKIL for-
ward primer: 5-GTTAA GCGAA CCTGT ACTTC
TGT-3, reverse primer: 5- GTAGG CGACA TGCTT
TCTTG G-3; MET forward primer: 5-GTCGG AGTAG
AGCGT CGAGA-3, reverse primer: 5-CAGCG CGATC
AGGTA GAGC-3; TOP2A forward primer: 5-ACCAT
TGCAG CCTGT AAATG A-3, reverse primer: 5-
GGGCG GAGCA AAATA TGTTC C-3; ADAM12 for-
ward primer: 5-TCAAC CTGGA TACCC GATTC C-3,
reverse primer: 5-GCTCT GTCTG CCGAT GGAG-3;
VCAN forward primer: 5-GTAAC CCATG CGCTA
CATAA AGT-3, reverse primer: 5-GGCAA AGTAG
GCATC GTTGA AA-3. The following primers were
used for full MET 3UTR application: MET 3′UTR for-
ward primer: 5-TCACT GCCTG ACCTT TA-3, MET
3′UTR reverse primer: 5-ATCAC TTACT CCCAC
AAT-3. The siRNA nucleotide for MET was used as fol-
lows: siRNA-MET forward: 5-GUGCC ACUAA CUACA
UUUAU U-3, siRNA-MET reverse: 5-UAAAU GUAGU
UAGUG GCACU U-3.Statistical analysis
The results are presented as means ± SEM, and the data
were analyzed with Student’s t test. A value of p < 0.05
was considered statistically significant.
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MicroRNA expression profile in gastric cancer
Comparison of peritoneal metastatic tissues with paired
primary foci samples of GC using hierarchical clustering
analysis revealed systematic variation in the expression
of miRNAs and genes (Figure 1A and B). Our data sug-
gests that a set of miRNAs and genes is frequently aber-
rantly expressed in the peritoneal metastatic tissues of
GC. In addition, we also found that some previously well
proved molecules, such as miR-7 [18], miR-25 [17],
TOB1 and IGF1R, were not be identified in our microar-
rays. We thought these difference may be induced by di-
versity of clinical samples came from different areas.
The miRNA-gene-network was assembled with the goal
of identifying the key miRNAs that regulate tumor-
associated gene expression during the progression of
tumor metastasis. Because coexpression modules probably
correspond to biological pathways, we focused on coex-
pression modules that are associated with a high number
of protein-coding genes. Furthermore, NCBI RefSeq de-
tails the functions of many genes, which aided our identifi-
cation of GC-associated genes. Using this method, we
characterized the role of miR-144 in the peritoneal meta-
static foci of GC. In the cancer coexpression network,Figure 1 Core miRNA-gene network, including 8 key miRNAs and their tar
that were differentially expressed between metastatic tissues in the periton
Expression values are represented in shades of red and green, indicating ex
samples. (C) The miRNA-gene network shows the relationships between 8
regulate. The colors indicate the annotated expression levels of the miRNAmiR-144 is connected to 6 protein-coding genes that are
involved in tumor growth and metastasis (Figure 1C).
Regulatory role of miR-144 in gastric cancer metastasis
To investigate miR-144 function, we first examined miR-
144 levels in a panel of 6 human GC cell lines. As shown
in Figure 2A, we selected AGS, characterized with up-
regulated miR-144, and SNU-5, characterized with
downregulated miR-144, for further study. The AGS cell
line was derived from gastric tumor fragments that were
resected from a patient who had received no prior ther-
apy, while SNU-5 was derived from ascites of a patient
with poorly differentiated carcinoma of the stomach.
In our study, we observed a close association between
miR-144 loss and metastases in GC (Figure 1A and C).
Correspondingly, earlier studies have documented miR-
144-based inhibition of tumor cell migration and invasion
in epithelial squamous cell carcinoma. We hypothesized
that reintroduction of miR-144 expression would sup-
press cancer cell migration. Suitably, introduction of
miR-144 expression inhibited cell migration in SNU-5
(Figure 2B). Compared to SNU-5, AGS cells have a rela-
tively higher level of endogenous miR-144 expression. Un-
surprisingly, inhibition of miR-144 increased AGS cellgets. Hierarchical clustering analysis of 27 miRNAs (A) and 32 genes (B)
eal and paired primary samples of GC (greater than 2.0-fold; p < 0.05).
pression above and below the median expression value across all
key miRNAs and tumor-associated genes they are predicted to
s and genes.
Figure 2 MiR-144 suppresses the migration of GC cells. (A)
Expression levels of miR-144 were checked in a panel of 6 human
GC cell lines using real-time PCR method. (B) Migration of SNU-5
cells treated with miR-144 mimics was checked using no-matrigel
treated transwell chamber. (C) Migration of AGS cells treated with a
miR-144 inhibitor was checked using no-matrigel treated transwell
chamber. (***p < 0.001).
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sion assay using matrigel-treated transwell, and there is no
difference for invasive ability of SNU-5/AGS cells after
treated with miR-144/anti-miR-144 (Data not shown).
These results illustrated that miR-144 plays an important
role in migration but not in invasion of GC cells.
miR-144 affects MET expression
Through the ectopic expression of miR-144 in SNU-5
cells, we determined ADAM12, VCAN and METare puta-
tive miR-144 targets. As shown in Figure 3A, miR-144 ex-
pression dramatically affected the mRNA levels of
ADAM12, VCAN and MET. ADAM12, VCAN and MET
protein expression levels were also detected through west-
ern blot in cancer cells transfected with miR-144 mimics.
As shown in Figure 3B, only MET protein levels were
downregulated by miR-144. This indicates that miR-144
affects MET expression at the transcriptional level, per-
haps through cleavage or destabilization of the mRNAstructure. However, we also found the ADAM12 and
VCAN protein levels are not decreased by exogenous
introduction of miR-144. We thought that mRNA and
protein levels cannot be directly correlated because of dif-
ferent half-life. We also thought they showed that may be
due to the presence of miR-144 that was continuously
repressing translation in one case but not the other. The
MET:miR-144 interaction was also demonstrated in living
cells by RNA-CHIP assay. In fact, endogenous miR-144
was found associated with endogenous MET in anti-MET
but not anti-IgG immunoprecipitates from cells (Figure 3C).
Using bioinformatic-based analysis, we identified a sin-
gle miRNA binding site for miR-144 in the 3′ UTR of
MET mRNA (Figure 3D). To test if miR-144 directly
binds the 3′-UTR of MET mRNA, we performed lucifer-
ase reporter assays in SNU-5 cells. PCR-derived frag-
ments from MET 3′UTR were inserted into the pGL3
control vector at Xba1 site (LUC-MET 3′UTR). Co-
transfection of LUC-MET 3′UTR and miR-144 mimics
in SNU-5 cells resulted in a decreased luciferase signal
(compared to miR-NC), confirming that binding of
miR-144 to the 3′UTR of MET has a direct inhibitory
effect (Figure 3E). The reverse experiment, accomplished
by blocking endogenous miR-144 production with a miR-
144 inhibitor in AGS cells, resulted in increased luciferase
signal (Figure 3F). A mutated luciferase reporter at the
miR-144 binding site was also constructed (Figure 3D).
Mutation of the miRNA binding site abolished miR-144-
mediated inhibition of luciferase activity (Figure 3G).
These data suggest that the 1430–1436 position of the
MET 3′UTR is critical for miR-144-mediated gene
regulation.MET mediates the miR-144-induced resistance to
migration
Using real-time PCR, MET expression levels were de-
termined for six human GC cell lines. As shown, cell
lines with “downregulated” miR-144 levels have higher
amounts of MET as compared to cell lines with “upreg-
ulated” miR-144 levels (Figure 4A). Using nonparametric
tests, we determined a significant inverse correlation
between MET mRNA and miR-144 expression in the
GC metastatic samples (Figure 4B).
The MET protein functions as a receptor tyrosine kin-
ase and plays a pivotal role in the promotion of cellular
growth and migration by transducing extracellular stim-
uli to intracellular signaling circuits. A prominent com-
ponent of the intracellular signaling machinery is the
PI3K (phosphoinositide 3-kinase) pathway [20,21]. Be-
cause miR-144 inhibits MET expression, we hypothe-
sized that miR-144 could ultimately decrease Akt
phosphorylation and activation through decreased MET
signaling. Accordingly, we examined Akt phosphorylation
Figure 3 Expression of MET was regulated by miR-144. (A) mRNA levels of putative miR-144 targets were examined by real-time PCR in SNU-5
cells transfected with miR-144 mimics or miR-NC. (B) Protein levels of putative miR-144 targets were examined by western blotting in SNU-5 cells
transfected with miR-144 mimics or miR-NC. (C) The % input recoveries of the RNA-ChIP reactions illustrates the enrichment by MET antibody.
RNA-ChIP assay for miR-144 performed on anti-MET antibody from lysates of cells. RNA-ChIP with a nonrelated IgG served as controls. (D) A
schematic picture of the predicted miR-144 binding site in the 3′UTR of MET. (E) SNU-5 cells were transiently co-transfected with LUC-MET 3′UTR
and miR-144 mimic. (F) AGS cells were transiently co-transfected with LUC-MET 3′UTR and a miR-144 inhibitor. (G) Mutating of the miR-144
binding site in MET 3′UTR abolished the miR-144-induced luciferase activity suppression. Luciferase activity was measured after 24 h and
normalised to the co-transfected Renilla. (*p < 0.05; **p < 0.01; ***p < 0.001).
Liu et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:35 Page 6 of 9levels after miR-144 overexpression and observed a signifi-
cant decrease of Akt phosphorylation (Figure 4C).
We decided to investigate whether miR-144-induced
MET downregulation had an effect on tumor cell migra-
tion and proliferation. We transfected miR-144 and
siRNA for MET (siRNA-MET) in SNU-5 cells. Cell mi-
gration was evaluated 16 h after transfection by transwell
assay, while cell proliferation was determined through
CCK-8. As shown in Figures 4D and E, transfection with
miR-144 inhibited cell migration and proliferation as
compared to control. Similarly, decreasing MET protein
expression using siRNA also decreased tumor cell mi-
gration and proliferation.
To determine whether MET is the critical mediator of
miR-144’s effect on cellular migration and proliferation,
we constructed two MET expression vector. One of
which contains only the open reading frame sequence of
MET gene (MET-ORF), and another vector contains the
full length nucleotide of MET gene including 3′UTR se-
quence (MET-full long). We then performed western
blot analysis 48 h after transfection of MET-ORF/MET-
full long into miR-144 mimics-treated SNU-5 cells(Figure 4F). Compared to the negative control group
(Empty vector), ectopic expression of MET-ORF signifi-
cantly increased the total expression of MET and
phosphorylated Akt. Furthermore, expression of the
MET-ORF promoted migration and proliferation of GC
cells (Figure 4G and H). Overexpression of MET abol-
ished miR-144-induced inhibition of cell migration and
proliferation. In contrast, the protein level of MET and
phosphorylated-AKT increased in AGS cells treated with
anti-miR-144 (Figure 4I), and blocking of miR-144 also
promoted the migration and proliferation of AGS cells
(Figure 4J and K). These results indicate that MET is a
critical target for the anti-migration effect of miR-144 in
human GC cells.
Discussion
In this study, we have identified non-overlapping signa-
tures of a small number of miRNAs and genes that are
aberrantly expressed in peritoneal metastatic tissues of
GC, as compared to paired primary tissues. Analysis of
miRNA and gene expression profiles in the miRNA-
gene-network identified miR-144 as a regulator of major
Figure 4 MET modulation accounts for the antimetastatic effect of miR-144. (A)Western blot showing MET expression in a set of human GC cell lines. (B)
A significant inverse correlation is observed between the miR-144 and MET expression levels in the GC tissues (n = 52). (C) The MET and phosphorylated
Akt were inhibited by the forced expression of miR-144 or siRNA-MET. (D, E) The effects of miR-144 or siRNA-MET on the migration and proliferation were
determined in SNU-5 cells. (F) The MET and phosphorylated Akt were restored by the overexpression of MET in miR-144 mimics-treated SNU-5 cells. (G, H)
The effects of miR-144 combined with MET-ORF on the migration and proliferation of SNU-5 cells. (I) The MET and phosphorylated Akt were up-regulated
by blocking of miR-144 in AGS cells. (J, K) The effects of anti-miR-144 on the migration and proliferation of AGS cells.
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GC patients with peritoneal metastases had lower miR-
144 expression levels than patients without metastases.
This finding implicates miR-144 as a potential tumorsuppressor in GC. Furthermore, miR-144 is associated
with the mechanisms of metastasis. Our results corres-
pond with the results of earlier studies on the role of miR-
144 in cancer proliferation, migration, and invasion
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ing the A disintegrin and metalloproteinase (ADAM) pro-
tein family member ADAMTS5. MicroRNA dysregulation
is associated with increased tumor invasiveness and me-
tastasis, as well as reduced patient prognosis in certain
epithelial cancers [24]. We further investigated the role of
miR-144 deregulation in GC. We studied the effect of
miR-144 expression in the SNU-5 cell line, as it is charac-
terized by low expression of miR-144. Ectopic expression
of miR-144 in SNU-5 cells results in profound phenotypic
changes, such as decreased migration. The reverse experi-
ment, blocking miR-144 expression, was conducted in the
AGS cell line, which has a relatively high endogenous level
of miR-144 expression. Inhibition of miR-144 expression
resulted in increased AGS cell migration.
To investigate the mechanism behind miR-144-
dependent decreased migration of GC, we identified the
putative targets for miR-144 as predicted by miRNA-
gene-network. miR-144 overexpression can reduce MET
expression at both mRNA and protein levels, and corres-
pondingly, luciferase reporter assays revealed that miR-
144 can directly interact with the MET 3′UTR. We then
evaluated MET expression levels in a cohort of 52 GC
patients and found that miR-144 levels are inversely cor-
related to MET expression. For that reason, we hypothe-
sized that miR-144 inhibits GC tumorigenesis by
targeting MET expression. MET has also been described
as a miR-34a/c target in other cellular models and is
known to promote motility and the invasive capability of
tumor cells. Overexpression of MET is closely correlated
with tumor invasion and patient prognosis in GC [6]. In
GC, MET overexpression is an independent prognostic
factor and potential drug target. Furthermore, MET
overexpression can predict which patients may benefit
from targeted therapy with MET inhibitors [25]. In our
study, MET expression was significantly associated with
GC differentiation, TNM and metastasis [26]. We deter-
mined that changes in cell proliferation and migration
through miR-144 could be exerted through the regula-
tion of MET expression. miR-144 repression leads to in-
creased levels of MET, which may explain the metastasis
phenotype of miR-144-depleted cells. Interestingly, miR-
144 influenced hepatocyte growth factor (HGF) signal-
ing. HGF, as the ligand of MET, can induce the
activation of MET in epithelial cells. While MET overex-
pression could not completely restore GC tumorigenic
qualities, GC cell migration and proliferation were par-
tially restored after MET overexpression. Therefore,
miR-144 may regulate other genes in GC cells. Previous
studies have shown that MET can induce GC tumorigen-
esis through the activation of the PI3K pathway. In this
study, we found that miR-144 significantly attenuated Akt
phosphorylation, and that Akt phosphorylation was com-
pletely restored with overexpression of MET. Our findingssuggest that miR-144 regulates Akt phosphorylation
through MET regulation in GC.
In conclusion, our study identified a basis for the de-
creased level of miR-144 seen in GC metastatic tissues.
miR-144 was identified as a potential tumor suppressor
in GC and has been associated with the mechanisms of
GC metastasis. Furthermore, miR-144 inhibits GC
tumorigenesis by targeting MET, and subsequently, the
PI3K/Akt pathway. To our knowledge, this is the first
time miR-144 has been shown to target MET in GC
cells. Therefore, further studies exploring the anticancer
role of miR-144 may contribute to the development of
new therapeutic strategies for GC.
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